
PROCLIPI Study







PROGNOSTIC Modelling in CTCL: The PROCLIPI study

PROspective **C**utaneous **L**ymphoma International **P**rognostic Index Study PI's – Julia Scarisbrick, U Birmingham, UK & Youn Kim – U Stanford, CA, USA On Behalf of the EORTC Gp & Cutaneous Lymphoma International Consortium









PROspective **C**utaneous Lymphoma International **P**rognostic Index Study

- The PROCLIPI study opened 2015 collects well-defined parameters at first diagnosis, stage progression and annual follow up of MF/SS
 - ➤ Clinical
 - Pathological
 - Nodal
 - ➤ Haematological
 - Genotypic
 - Treatment
 - Biobank Material





- Prognostic variables are tested against overall & progression free survival (PFS)
- Treatments responses will be compared along side time to next treatment, PFS and quality of life
- We aim to recruit a minimum of 1500 patients with MF/SS over the 5 year study period, survival data for 10+ years
- 20% of patients will be used in the validation set









75 Registered PROCLIPI Centres

Principal Investigator	Centre Address
Sean Whittaker	St Thomas' Hospital, London, UK
Julia Scarisbrick	University Hospitals Birmingham, Birmingham, UK
Christiane Querfeld	City Of Hope National Medical Center, California, US
Evangelia Papadavid	Athens University Medical School, Athens, Greece
Youn Kim	Stanford University, California, USA
Martine Bagot	Hospital St Louis, Paris, France
Maarten Vermeer	Leiden University Medical Centre, Leiden, The Netherlands
Emilia Hodak	Rabin Medical Center, Israel
Emmanuella Guenova	University Hospital Zurich, Zurich, Switzerland
Jose Sanches	University Of Sao Paulo Medical School, Sao Paulo, Brazil
Miles Prince	Peter Maccallum Cancer Centre, Melbourne, Australia
Octavio Servitje	Hospital Universatari de Bellvitge, Barcelona, Spain
Rudolf Stadler	Johannes Wesling Medical Centre, Minden, Germany
Richard Cowan	Christie Hospital, Manchester, UK
Oleg Akilov	University Of Pittsburgh School Of Medicine, Pennsylvania, USA
Pietro Quaglino	University of Turin (Torino), Turin, Italy
Emilio Berti	University of Milano, Milan, Italy
Ulrike Wehkamp	Kiel University Hospital, Kiel, Germany
Anne-Marie Busschots	University Hospital Louvain, Louvain, Belgium
Teresa Estrach	Hospital Clinico, University of Barcelona, Spain
Marta Marschalko	Semmelweis University, Budapest, Hungary
Robert Knobler	University of Vienna Medical School, Vienna, Austria
Katerina (Aikaterini) Patsatsi	Aristotle University of Thessalonik, Thessalonik, Greece
Pablo Oritz-Romero	Hospital 12 De Octubre, Madrid, Spain
Annamari Ranki	Helsinki University Central Hospital, Helsinki, Finland
John Frew	Newcastle Upon Tyne NHS Trust, Newcastle, UK
Rubeta Matin	Oxford Radcliffe Hospital, Oxford, UK
Emmanuella Guenova	Hopital De Beaumonth, Lausanne, Switzerland
Giles Dunhill	Bristol Royal Infirmary, Bristol, UK
Marie Beylot-Barry	CHU Hospital de Bordeaux, Bordeaux, France
Meenal Kheterpal	Memorial Sloan Kettering Cancer Center, US
Rachel Wachsmuth	Royal Devon & Exeter Hospital, Exeter, UK
Andrew Bates	University Hospital Southampton, Southampton, UK
Dr. Christina Mitteldorf	HELIOS Klinikum Hildesheim GmbH, Hildesheim, Germany
Ramon Puiol	Hospital del Mar. Barcelona, Barcelona, Spain
Marion Wobser	University Hospital Wuerzburg, Wuerzburg, Germany
Mike Bayne	University Hospitals Dorset NHS Foundation Trust, UK
Paula Enz	Hospital Italiano De Buenos Aires, Buenos Aires, Argentina

Duin singly have still a	Control Address
Principal Investigator	Centre Address
Detlev Klemke	Stadtisches Klinikum Karlsruhe, Karlsruhe, Germany
Cesare Massone	Galliera Trust, Genoa, Italy
Dr Arvind Arumainathan	Royal Liverpool Hospital, Liverpool, UK
Franz Trautinger	University St Poelten. Dermatology, St Poelten, Austria
Nicola Pimpinelli	University of Florence, Florence, Italy
Kim Benstead	Gloustershire Hospitals NHS Trust, Gloustershire, UK
Pam Mackay	Beatson West Of Scotland Cancer Centre, Glasgow, UK
Tomomitsu Miyagaki	University of Tokyo, Tokyo, Japan
Claus-Detlev Klemke	University Medical Center Mannheim, Mannheim, Germany
Deborah Turner	Torbay Hospital, Torbay, UK
Pier Luigi Zinzani	Università di Bologna, Bologna, Italy
Mona Abdel Halim	Ain Shams University, Cairo, Egypt
Jan Nicolay	Universitätsmedizin Mannheim, Mannheim, Germany
David Wada	University of Utah - Huntsman Cancer Institute, Utah, USA
Ellen Kim	University of Pennsylvania, Pennsylvania, USA
Eugenia Piliotis	Sunnybrook Health Sciences Centre - Odette Cancer Center USCLC
Chalid Assaf	Le Charite Hospital, Berlin, Germany OR HELIOS Klinikum Krefeld, Germany
Francesco D Amore	Aarhus University, Denmark
Di Gilson	St James University Hospital, Leeds, UK
Eve Gallop-Evans	Velindre Hospital, Cardiff, Wales, UK
Adam Forbes	Royal Cornwall Hospitals NHS Trust, Truro, Cornwall, UK
Eleanor James	Nottingham University Hospitals, Nottingham, UK.
Antonio Cozzio	St Gallen Hospital, St Gallen, Switzerland
Lorenzo Cerroni	Department of Dermatology, University of Graz, Austria
Ricardo Fernández de Misa Cabrera	Medical University, Tennerife,
Rose Moritz	Universitätshautklinik Münster, Münster, Germany
Ilan Goldberg	Tel Aviv Sourasky Medical Center
Miguel A Piris	Hospital Universitario Marques de Valdecilla, Santander, Spain
Christina Mitteldorf	University Of Goettingen, Germany
Ale Gru	University Of Virginia, Virginia, USA
Yang Wang	Peking University First Hospital, Beijing, China
Joan Guitart	Northwestern University, Chicago, Illinois, USA
Larisa Geskin	University Of Columbia, New York, USA
Ellen Kim	Hospital Of The University Of Pennsylvania, Philadelphia, US
Salma Machan	Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
An Bervoets	Antwerp University Hospital, Belgium










Spatz Foundation


PROCLIPI: 2219 patients recruited; 1700 early, 519 late stage, 52 sites, from 10 countries 6 continents 0

from 19 countries, 6 continents	0	20	40	60	80	100	120	140	160
Ain Shams University, Cairo, Egypt	_								
Aristotle University of Thessalonik, in Papageorgiou General Hospital, Greece	-								
Áthens University Medical School, Greece Beatson West of Scotland Cancer Centre	-					-			
Bristol Royal Infirmary, Bristol, UK	-								
Christie Hospital, Manchester UK	-								
CHU Hospital de Bordeaux, Bordeaux, France									
City Of Hope National Medical Center, Duarte, California, US	_								
Galliera Trust, Genoa Italy Gloustershire Hospitals NHS Trust, Gloustershire, UK	-								
Hopital De Beaumont, Lausanne, CH	-								
HELIOS Klinikum Hildesheim GmbH	-								
Helsinki University Central Hospital, Finland	_								
Hospital 12 de Octubre, Madrid, Spain									
Hospital Clinico, University of Barcelona	_								
Hospital del Mar Barcelona, Barcelona, Spain Hospital Italiano De Buenos Aires, Argentina	_								
Hospital Italiano De Buenos Aires, Argentina Hospital St Louis, Paris, France	-								
Hospital Universatari de Bellvitge, Barcelona, Spain	-								
Johannes Wesling Medical Centre, Minden, Germany									
Leiden University Medical Centre. The Netherlands									
Memorial Sloan Kettering.	•	-							
Newcastle Upon Tyne NHS Trust, Newcastle, UK	-								
Northwestern University, Chicago, Illinois, USA Oxford Radcliffe Hospital, Oxford UK	-								
Peter Maccallum Cancer Centre, Melbourne, Australia	-								
Rabin Medical Center, Israel	-								
Roval Devon & Exeter Hospital, Exeter, UK									
Royal Liverpool Hospital, Liverpool, UK									
Semmelweis University, Budapest, Hungary	-								
St Thomas' Hospital, London, UK Stadtisches Klinikum Karlsruhe, Karlsruhe, Germany	-								
Stanford University Hospital, California, USA									
Torbay Hospital, Torbay, UK	-								
Università di Bologna, Italy	_								
University Hospital Kiel, Kiel, Ğermany	_								
University Hospital Louvain, Belgium University Hospital Southampton, Southampton, UK	-								
University Hospital Southampton, Southampton, Gr	-								
University Hospital Zurich, Switzerland									
University Hospitals Birmingham, UK									
University Hospitals Dorset NHS Foundation Trust (UHDFT).	_								
Úniversity Medical Center Mannheim, Germany									
Úniversity Of Columbia, New York, USÁ University of Florence, Italy	-								
University of Milano, Italy	-								
University Of Pittsburgh School Of Medicine, Pennsylvania, USA									
University Of Sao Paulo Medical School, Brazil, South America			-						
University of Tokyo, Tokyo, Japan]								
University of Turin (Torino), Italy	_								
University of Vienna Medical School, Austria	-								
rsity St Poelten & Karl Landsteiner Institute of Dermatology, St Poelten, Austria									

Recruitment number by 19 participating countries








Rescruitdate (Month)











Central Review Team : Clinical, histopathological & immunohistochemical

Central Review Team Early Stage;



Rein Willemze

Virtual review of clinical and pathological photomicrographs followed by real-time review if required Pass Rate 772/922 (83.7%) 150 failed 20 restaged advanced, 27 awaiting real time review, 16 incomplete data fro review, 114 non diagnsotic





Lorenzo Cerroni


Central Review Team Late stage; Virtual review of scanned slides

Ale Gru, Virginia, US



Maxime Battistella, Paris





Melissa Pulitzer (MSKCC) Joan Guitart (Northwestern) Carlos Torres Cabala MD Anderson





Helmut Beltraminelli, Zurich Joya Pawade, Bristol UK

Haematopathology Panel







Andrew Feldman, Mayo

Nancy L Harris, MGH Miguel Angel Piris, Madrid

Maxime Battistella. Paris

Early stage data: 1700 patients (77%)




Stage IA; <10% patches & plaques n=847 patients (50%)

Stage IB; >10% patches & plaques n=711 patients (42%)



Stage IIA; Patches & plaques with enlarged lymph nodes showing dermatopathic changes or early involvement with MF (not effaced) n=142 patients (8%)











PROCLIPI Study

Late stage data: 460 patients (23%)



Stage IIB; tumour stage n=157 patients (34%)

Erythroderma IIIA-IVA1 n= 252 patients (55%)

Stage IIIA; low blood tumour burden (B0) n=50 patients (11%) Stage IIIB; Moderate blood tumour burden (B1) n=50 patients (11%) Stage IVA1; high tumour burden (B2) n=152 patients (36%)





Stage IVA2; Lymph nodes showing effaced lymph nodes n=36 patients (8%)

Stage IVB; Visceral disease n=15 patients (3%)









Clinical Data Set on 1818 patients – median FU 29mnths [23-31]

- Median age early stage (IA-IIA) is 58 years which is significantly younger than late stages IIB-IVB at 66 years (p<0.0001)
- Patients presented in advanced disease had a shorter duration of disease prior to diagnosis at 12 months compared to 24 months in early stages (p=0.0001)
- Median QOL significant different in Early vs Late stage (Global p<0.0001, Symptoms p<0.0001, Emotions p=0.0016, Functioning P<0.0001)

	Early	IIB	IIIA	IIIB	IVA(1)	IVA(2)	IVB	Late
Number of Patients	1409	157 (34%)	50(11%)	50 (11%)	152 (33%)	36 (8%)	15 (3%)	460
Classical Mycosis Fungoides	1132 (80.3%)	105 (66.9%)	27 (54.0%)	13 (26.0%)	6 (10.5%)	8 (22.2%)	6 (40.0%)	175 (38.0%)
Folliculotropic Mycosis Fungoides	200 (14.2%)	29 (18.5%)	6 (12.0%)	5 (10.0%)	4 (2.6%)	4 (11.1%)	2 (13.3%)	50 (10.9%)
Median age years (IQR)	58 (44-69)	65	64	67.5	68	65	56 🤇	66 (55-74)
m:f ratio	1.7:1	2.2:1	2.8:1	1.9:1	1.6:1	1.1:1	2.0:1	1.9:1
Median duration MF-like lesions, months	24 (2-74)	17	24	17	6	22.5	15	12 (0-48)
Median MSWAT score	15 (6-35)	39	100	100	90	90	65	84 (44.5- 104.5)
No. with stage progression (to advanced stage)	157 (90)	8	8	10	5	1	0	32
Number of deaths	73 (5.2%)	41 (26.1%)	13 (26.0%)	13 (26.0%)	38 (25.0%)	17 (47.2%)	7 (46.7%)	129 (28.0%)
Number of lymphoma related deaths	25 (1.8%)	26 (16.6%)	4 (8.0%)	7 (14.0%)	19 (12.5%)	14 (38.9%)	4 (26.7%)	74 (16.1%)
QOL Global (Median (IQR))	25.3 (137-41.3)	34.9 21.2-61.5)	36.0 (15.9-57.5)	46.2 (40.9-62.3)	46.4 (28.7-66.9)	46.8 (34.9-68.0)	55.9 (34.6-66.1)	43.9 (27-62.8)

Associations with progression to advanced stage in early stage disease has been reported in 90 (6%)

		Numbers early stage patients progressed to advanced stages	Total	P-Value		
	B0	39 (7.3%)	532			
	B1	10 (9.6%)	104	B0 v B1 p=0.424		
	Вх	41 (5.4%)	764			
	NO	71 (5.5%)	1284	N0 vs Not N0 p<0.0001		
	N1	4 (21.1%)	19	N0 vs Not (restricted to		
	N2	0	2	N1/N2) P=0.029		
Ethnicity isn't	<mark>NX</mark>	15 (15.8%)	95			
ecorded very well -	Age > 60 yrs	56 (8.9%)	630	p=0.001		
10% missing no	Male Sex	61(7.0%)	873	P=0.273		
~	Low ALC	13 (10.6%)	123	p=0.151		
ignificance	Raised Serum LDH	<mark>18 (11.4%)</mark>	<mark>157</mark>	P=0.034		
	Identical Clone on Blood	6 (9.4%)	64	p=0.998		
	Plaque (T1b or T2b)	<mark>69 (10.9%)</mark>	<mark>634</mark>	P<0.001		
	Folliculotropism	<mark>27 (10.8%)</mark>	<mark>250</mark>	P=0.002		
	LCT	<mark>10 (34.5%)</mark>	<mark>29</mark>	P<0.001		

Associated with progression to advanced stage:

- Nx-N2 •
- Raised LDH
- **Presence plaques**
- **Folliculotropism**
- LCT in skin

Key: **Significant** Not Significant

Multivariable analysis for stage progression of patients presenting in early stage using Cox regression


NO	1 (reference Value)	
N1	4.19 (1.62-10.84)	<mark>p = 0.003</mark>
N2	2.28 (0.31-16.64)	p = 0.417
Nx	2.09 (1.19-3.67)	<mark>p = 0.010</mark>
Over 60	1.97 (1.30-2.97)	<mark>p = 0.001</mark>
LCT	3.99 (2.14-7.44)	<mark>p<0.001</mark>
Folliculotropic MF	1.52 (0.97-2.39)	<mark>p = 0.066</mark>
Lyp like Lesions	0.86 (0.31-2.40)	p = 0.773
Hypopigmentation	0.96 (0.43-2.13)	p = 0.921
Plaques	2.81 (1.72-4.56)	<mark>p <0.001</mark>

Associations with death (disease specific) in late stage disease has been reported in 74 of 460 patients (16.1%)

	Numbers late stage patients died	Total	P-Value	
T1	2(14.3%)	14]
T2	6 (8.6%)	70		
тз	32 (18.8%)	170	P=0.221 (t3 vs Not T3)	
T4	34 (16.5%)	206	P=0.826 (T4 vs Not T4)	
во	23 (20.4%)	113		
B1	10(17.5%)	57	B0, B1 v B2 p=0.396	Associated with disease
B2	23 (15.8%)	146		specific deaths:
Вх	18 (12.5%)	144		• <mark>Nx-N3</mark> • N3
NO	24 (9.9%)	243		 Age >60years
N1	3 (8.3%)	36	N0 vs Not N0 p<0.001 N0 vs Not (restricted to N1/N2/N3)	
N2	2 (13.3%)	15	P=0.003	
N3	15 (39.5%)	38	<mark>N3 vs not N3 p<0.001</mark>	
NX	30 (23.4%)	128		
Age > 60 yrs	55(18.6%)	296	<mark>p=0.050</mark>	
Male sex	50 (16.7%)	300	P=0.643	
Low ALC	14 (26.9%)	52	p=0.148	
Raised Serum LDH	38 (20.0%)	190	P=0.187	Key:
Identical Clone on Blood	25(26.9%)	93	P=0.428	Significant Not Significant
LCT in skin	15 (23.8%)	63	P=0.136	
Folliculotropism	17 (27.0%)	63	P=0.087	

PROCLIPI Study

Overall (Disease Specific survival) – Advanced Stage



IVA2 vs not IVA2 (Excluding IVB) p=0.002









JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

J Clin Oncology. 2015;33(32):3766-73



Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Julia J. Scarisbrick, H. Miles Prince, Maarten H. Vermeer, Pietro Quaglino, Steven Horwitz, Pierluigi Porcu, Rudolf Stadler, Gary S. Wood, Marie Beylot-Barry, Anne Pham-Ledard, Francine Foss, Michael Girardi, Martine Bagot, Laurence Michel, Maxime Battistella, Joan Guitart, Timothy M. Kuzel, Maria Estela Martinez-Escala, Teresa Estrach, Evangelia Papadavid, Christina Antoniou, Dimitis Rigopoulos, Vassilki Nikolaou, Makoto Sugaya, Tomomitsu Miyagaki, Robert Gniadecki, José Antonio Sanches, Jade Cury-Martins, Denis Miyashiro, Octavio Servitje, Cristina Muniesa, Emilio Berti, Francesco Onida, Laura Corti, Emilia Hodak, Iris Amitay-Laish, Pablo L. Ortiz-Romero, Jose L. Rodríguez-Peralto, Robert Knobler, Stefanie Porkert, Wolfgang Bauer, Nicola Pimpinelli, Vieri Grandi, Richard Cowan, Alain Rook, Ellen Kim, Alessandro Pileri, Annalisa Patrizi, Ramon M. Pujol, Henry Wong, Kelly Tyler, Rene Stranzenbach, Christiane Querfeld, Paolo Fava, Milena Maule, Rein Willemze, Felicity Evison, Stephen Morris, Robert Twigger, Rakhshandra Talpur, Jinah Kim, Grant Ognibene, Shufeng Li, Mahkam Tavallaee, Richard T. Hoppe, Madeleine Duvic, Sean J. Whittaker, and Youn H. Kim

Listen to the podcast by Dr Pinter-Brown at www.jco.org/podcasts









Retrospective Data as Prognostic Index


- Prognostic modelling combined these 4 factors into a prognostic index
 - Stage IV
 - Age >60 years
 - Raised LDH
 - LCT in skin
- Divides patients into risk groups for disease progression
 - Low-risk = 0-1 factors
 - Intermediate-risk = 2 factors
 - High-risk = 3-4 factors
- Separated advanced cohort into
 - Low-risk: n = 327 (IIB n=166, III n=134, IV n=27)
 - Intermediate-risk: n= 329 (IIB n=91, III n=82, IV n=156)
 - High-risk: n = 201 (IIB n=20, III n=4, IV n=177)











Stratifying PROCLIPI advanced stage patients using the prognostic index developed by retro CLIC

	Number of Advanced Stage Patients	IIB	IIIA	IIIB	IVA1	IVA2	IVB
Low	120	68	20	17	11	4	0
Intermediate	131	36	16	17	46	9	7
High	77	14	1	1	39	19	3
TOTAL	328	118	37	35	96	32	10
				CANCER			EODT










PROCLIPI Study

Kaplan Meier of Survival According to CLIC Prognostic Index at Diagnosis in MF/SS from the PROCLIPI Study











С	inical		Blood	Skin Biopsy	Lymph Nodes	Bone Marrow C	Other Visceral	Clonality	reatments Fed Bi	obank Death	Explorator	y QOL Skindex 29
Trea	atme	nt										
+												
			Visit	Date Of Visit	Туре	Reason for Stopping Therapy	Best Response	Date Started	MSWAT at Start of Treatment	Date Ended	MSWAT at End of Treatment	Other
	· ,	× 1		03/10/2016	Methotrexate Low Dose < 35mg per week	Stage Progression	PD	21/10/2016	60	12/12/2016	150	
-	• •	K 1		03/10/2016	Interferon alfa	Toxicity	PR	28/12/2016	150	01/11/2017	35	low lymphocytes
/	• ,	K 1		03/10/2016	ECP	Ongoing	SD	03/01/2017				last seen 22/6/18 - ECP ongoingTLI/ATG unrelated donor stem cell transplant with HLA- DQ mismatch, 13
-	• ;	× 2	2	24/12/2016	Oral Bexarotene	Toxicity	SD	29/05/2017	40	19/06/2017	40	
	• ;	× 4	L .	06/11/2017	Allogeneic Transplant	Treatment Course Complete	CR	07/02/2018	0	17/02/2018	0	relapse at oct 2018 skin DLI



New datasets for LCAL, CBCL

Global PROCLIPI Steering Committee

Youn Kim, Stanford, US Julia Scarisbrick, Birmingham, UK Pierluigi Porcu, Philadelphia, US Joan Guitart, NorthWestern, US Miles Prince, Melbourne, Aus Steve Horwitz, U Columbia, US Pietro Quaglino, Turin, Italy Maarten Vermeer, Leiden, NL Sean Whittaker, London, UK Robert Knobler, Vienna, Austria Emmie Hodak, Tel Aviv, Israel Lia Papadavid, Athens, Greece Pablo Ortiz, Madrid, Spain Martine Bagot, Paris, France Rudi Stadler, Minden, Germany Rein Willemze, Leiden, NL














'Working together for improved research'



"It always seems impossible until it's done" Mandela







